Your browser doesn't support javascript.
loading
Maximizing the value of phase III trials in immuno-oncology: A checklist from the Society for Immunotherapy of Cancer (SITC).
Atkins, Michael B; Abu-Sbeih, Hamzah; Ascierto, Paolo A; Bishop, Michael R; Chen, Daniel S; Dhodapkar, Madhav; Emens, Leisha A; Ernstoff, Marc S; Ferris, Robert L; Greten, Tim F; Gulley, James L; Herbst, Roy S; Humphrey, Rachel W; Larkin, James; Margolin, Kim A; Mazzarella, Luca; Ramalingam, Suresh S; Regan, Meredith M; Rini, Brian I; Sznol, Mario.
Affiliation
  • Atkins MB; Georgetown Lombardi Comprehensive Cancer Center, Washington, District of Columbia, USA mba41@Georgetown.edu.
  • Abu-Sbeih H; University of Missouri Kansas City, Kansas City, Missouri, USA.
  • Ascierto PA; Istituto Nazionale Tumori IRCCS Fondazione "G Pascale", Napoli, Italy.
  • Bishop MR; The David and Etta Jonas Center for Cellular Therapy, University of Chicago, Chicago, Illinois, USA.
  • Chen DS; Engenuity Life Sciences, Burlingame, California, USA.
  • Dhodapkar M; Center for Cancer Immunology, Winship Cancer Institute at Emory University, Atlanta, Georgia, USA.
  • Emens LA; UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA.
  • Ernstoff MS; DCTD/DTP-IOB, ImmunoOncology Branch, NCI, Bethesda, Maryland, USA.
  • Ferris RL; UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA.
  • Greten TF; Gastrointestinal Malignancies Section, National Cancer Institue CCR Liver Program, Bethesda, Maryland, USA.
  • Gulley JL; Center for Immuno-Oncology, National Cancer Institute, Bethesda, Maryland, USA.
  • Herbst RS; Yale Cancer Center, New Haven, Connecticut, USA.
  • Humphrey RW; Normunity, Inc, South San Francisco, California, USA.
  • Larkin J; Royal Marsden Hospital, London, UK.
  • Margolin KA; St. John's Cancer Institute, Santa Monica, California, USA.
  • Mazzarella L; Experimental Oncology, New Drug Development, European Instititue of Oncology IRCCS, Milan, Italy.
  • Ramalingam SS; Winship Cancer Institute of Emory University, Atlanta, Georgia, USA.
  • Regan MM; Dana-Farber/Harvard Cancer Center, Boston, Massachusetts, USA.
  • Rini BI; Harvard Medical School, Boston, Massachusetts, USA.
  • Sznol M; Ingram Cancer Center, Nashville, Tennessee, USA.
J Immunother Cancer ; 10(9)2022 09.
Article in En | MEDLINE | ID: mdl-36175037
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Clinical Trials as Topic / Programmed Cell Death 1 Receptor / Immunotherapy / Neoplasms Type of study: Prognostic_studies Limits: Animals Language: En Journal: J Immunother Cancer Year: 2022 Document type: Article Affiliation country:
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Clinical Trials as Topic / Programmed Cell Death 1 Receptor / Immunotherapy / Neoplasms Type of study: Prognostic_studies Limits: Animals Language: En Journal: J Immunother Cancer Year: 2022 Document type: Article Affiliation country: